Shots:
- AstraZeneca has reported P-III (FLAURA2) trial findings on Tagrisso + Pt-based CT as a 1L treatment of pts with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC
- The P-III (FLAURA2) trial assessed Tagrisso (80mg, QD, PO) + pemetrexed + cisplatin/carboplatin (Q3W for 4 cycles) followed by Tagrisso + pemetrexed maintenance (Q3W) vs Tagrisso alone in 557 EGFRm NSCLC pts
- As of June 12, 2025 (mFU: 51.2 vs 51.3mos.), the trial showed an mOS of 47.5 vs 37.6mos. At 57% data maturity, OS (2EP) was improved by 23%, with 63.1% vs 50.9% pts alive at 3yrs. & 49.1% vs 40.8% alive at 4yrs.; OS benefit was consistent across all subgroups. Data was presented at WCLC’25
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports P-III (BaxHTN) Trial Data on Baxdrostat for Uncontrolled or Treatment Resistant Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
